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Abstract
Cancer-related cognitive impairment (CRCI) adversely affects cancer patients. We had previously demonstrated that the
BDNF Val66Met genetic polymorphism is associated with lower odds of subjective CRCI in the multitasking and verbal
ability domains among breast cancer patients receiving chemotherapy. To further assess our previous findings, we eval-
uated the association of BDNF Val66Met polymorphism with subjective and objective CRCI in a temporally separate
cohort of patients and pooled findings from both the original (n = 145) and current (n = 193) cohorts in a meta-analysis.
Subjective CRCI was assessed using FACT-Cog. Objective CRCI was evaluated using computerized neuropsychological
tests. Genotyping was carried out using Sanger sequencing. The association of BDNF Val66Met genotypes and CRCI was
examined with logistic regression. A fixed-effect meta-analysis was conducted using the inverse variance method. In the
meta-analysis (n = 338), significantly lower odds of CRCI were associated with Met allele carriers based on the global
FACT-Cog score (OR = 0.52, 95% CI 0.29–0.94). Furthermore, Met allele carriers were at lower odds of developing
impairment in the domains of memory (OR = 0.34, 95% CI: 0.17–0.70), multitasking (OR = 0.33, 95% CI: 0.18–0.59),
and verbal ability (OR = 0.46, 95% CI: 0.24–0.88). Consistent with the previous study, lower odds of subjective CRCI
among patients with the BDNF Met allele was observed after adjusting for potential confounders in the multitasking
(OR = 0.30, 95% CI: 0.14–0.67) domain. In conclusion, carriers of the BDNF Met allele were protected against global
subjective CRCI, particularly in the domains of memory, multitasking, and verbal ability. Our findings further contribute
to the understanding of CRCI pathophysiology.
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Introduction
Commonly known in literature as “chemobrain” or
“chemofog,” subtle yet notable alterations in cognitive func-
tion are often observed in breast cancer patients receiving
chemotherapy [1]. Manifesting as both patient-reported
subjective complaints and objective changes detected by
neuropsychological tests, cancer-related cognitive impair-
ment (CRCI) has been reported to include memory loss,
concentration deficit, and the decreased ability to multitask
[2]. Evidence has shown that CRCI negatively affects the
quality of life of cancer patients and the ability to cope with
demands in their daily lives [3]. As its etiology is not yet
fully understood, CRCI remains a subject of significant
research. Ongoing work has suggested possible factors that
may influence the risk of CRCI, such as pro-inflammatory
cytokines, psychosocial determinants including anxiety
and fatigue, and numerous genetic markers [4–6]. Among
candidate genes that have been investigated are COMT,
APOE, and BDNF [6, 7].
The BDNF gene expresses brain-derived neurotrophic fac-
tor (BDNF), which is a neurotrophic factor vital for neuronal
survival, growth, and neural circuit maintenance [8]. The
BDNF Val66Met single nucleotide polymorphism (SNP),
which leads to substitution of valine with methionine at codon
66, is a functional polymorphism widely studied in neurolog-
ical conditions such as schizophrenia and Parkinson’s disease
[9, 10]. Our research group has discovered that the BDNF
Val66Met polymorphism is associated with a lower risk of
developing self-perceived CRCI in breast cancer patients [7],
where carriers of the Met allele had lower odds of reporting
subjective CRCI in the cognitive domains of verbal ability
(OR = 0.34, 95% CI = 0.12–0.90) and multitasking (OR =
0.37, 95% CI = 0.15–0.91). However, other studies have sug-
gested that carrying the Met allele may be associated with
poorer perseveration, verbal memory abilities, and task
switching [11]. Therefore, whether carriers of the Met allele
are truly protected against cognitive decline remains contro-
versial, implying that the BDNF Val66Met polymorphism
may contribute to varying cognitive function [11].
As false positives are commonly observed in genetic asso-
ciation studies [12], further replication attempts are required to
confirm associations that were initially observed, in order to
provide stronger evidence on the impact of genetic determi-
nants on CRCI. A deeper understanding of these genetic fac-
tors will allow the identification of cancer patients at a higher
risk of CRCI for potential interventions. Therefore, in this
study, we aim to evaluate the association of BDNF
Val66Met polymorphism with subjective and objective
CRCI in a temporally separate cohort of patients and pool
findings from both the original and current cohorts in a me-
ta-analysis.
Methods
Study Design
This was a multicenter, prospective cohort study conducted at
three ambulatory cancer centers between February 2014 and
December 2017 in Singapore. This study was approved by
SingHealth Institutional Review Board (CIRB2014/754/B)
and written informed consent was obtained from all patients.
Study Population
Eligible participants must fulfill the following inclusion
criteria: (i) at least 21 years old, (ii) diagnosed with stages I
to III breast cancer, (iii) scheduled to receive chemotherapy,
(iv) has no prior history of chemotherapy and/or radiotherapy,
(v) able to read and understand either English or Mandarin,
and (vi) has Eastern Cooperative Oncology Group (ECOG)
performance status score of 0 or 1.
Patients were excluded from the study if they were (i) in-
capable of providing verbal/written consent or (ii) diagnosed
with neuropsychiatric disorders and/or brain metastasis that
might result in poor cognitive function.
Study Procedures
Upon recruitment, demographic data and clinical information of
participants were collected via patient interviews and from elec-
tronic medical records. Participants were prospectively evaluated
at three time points: before start of chemotherapy (T1), 6 weeks
after start of chemotherapy (T2), and 12 weeks after start of che-
motherapy (T3). At each time point, participants completed assess-
ments of both subjective and objective CRCI. In addition, health-
related quality of life, anxiety, and fatiguewere assessed using self-
administered questionnaires. English andChinese versions of each
study tool were available. All assessments took approximately
45 min to complete and were conducted by trained interviewers.
Assessment of Subjective Cognitive Impairment
The Functional Assessment of Cancer Therapy–Cognitive
Function (FACT-Cog) version 3 was used to evaluate patients’
self-perceived CRCI within the past 7 days [13]. FACT-Cog
comprises 37 items in 6 domains of cognitive disturbances,
which are mental acuity, concentration, memory, verbal abil-
ity, functional interference, and multi-tasking ability. Each
item is evaluated on a 5-point Likert scale. Both English and
Chinese versions of FACT-Cog have been validated and dem-
onstrated satisfactory psychometric properties [14].
Subjective CRCI is defined as a reduction of at least 10.6
points in the FACT-Cog total score at T2 or T3 compared to
baseline based on a previously determined minimal clinically
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important difference (MCID). Decline in a particular cognitive
domain is defined as a reduction of at least 15% from a par-
ticipant’s baseline score at T2 or T3 [15].
Assessment of Objective Cognitive Impairment
Objective cognitive assessment was carried out using the
Cambridge Neuropsychological Test Automated Battery
(CANTAB), a language-independent neuropsychological
testing research software. In this study, the CANTAB test
battery contained five tests: reaction time (RTI), paired
associates learning (PAL), spatial working memory
(SWM), attention switching task (AST), and rapid visual
information processing (RVP) that assessed response
speed, learning and memory, working memory, multitask-
ing, and sustained attention, respectively, yielding a total
of nine measures. The direction of one measure, A′, was
reversed so higher scores indicate poorer cognitive perfor-
mance for all measures. These tests have been validated
and have shown sensitivity to capturing alterations in neu-
ropsychological performance [16–18].
Reliable change indices (RCI) were computed to reflect
cognitive changes in participants. RCI were obtained by
subtracting CANTAB scores at T2 or T3 from baseline scores,
adjusting for practice effects and dividing by the standard
error of difference. Practice effects and standard error of dif-
ference were estimated from a control population using simi-
lar testing intervals. Objective cognitive decline is defined as
an RCI of less than − 2 at either T2 or T3.
Assessment of Fatigue
Fatigue was evaluated with the Brief Fatigue Inventory (BFI)
[19]. BFI measures the severity of fatigue and the impact of
fatigue on daily functioning in the past 24 h on a numerical
scale of 0 to 10. Six aspects of daily functioning were
assessed: general activity, mood, walking ability, normal
work, relations with other people, and enjoyment of life. A
higher score indicates greater level of fatigue.
Assessment of Anxiety
The Beck Anxiety Inventory (BAI) was employed to measure
anxiety in participants [20, 21]. BAI is a validated question-
naire consisting of 21 items describing subjective, somatic, or
panic-related symptoms of anxiety on a scale of 0 to 3. A
higher total score indicates greater level of anxiety.
Assessment of Insomnia
The European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
assesses health-related quality of life (HRQoL). In this study,
we focused on the single-item scale rating insomnia, which is
measured on a 4-point Likert scale. A higher score indicates
increased severity of insomnia. Both English and Chinese
versions of QLQ-C30 have been validated for use in cancer
patients in Singapore [22, 23].
Genotyping
At baseline, a 10-ml blood sample was collected from partic-
ipants in an ethylene diamine tetraacetic acid (EDTA) tube and
centrifuged at 2500 rpm for 10 min within 40 min of collec-
tion. The buffy coat was extracted and at stored at − 80 °C
until analysis.
Using QIAamp DNA Blood Mini Kit (QIAGEN), geno-
mic DNA from the buffy coat was isolated. The region
with the BDNF Val66Met polymorphism was amplified
via polymerase chain reaction (PCR) using the following
specific and optimized primers: 5′-GGACTCTGGAGAGC
GTGAA-3 ′ (forward) and 5 ′-CGTGTACAAGTCTG
CGTCCT-3′ (reverse). Genotyping of the PCR products
was subsequently conducted by AITbiotech employing au-
tomated Sanger sequencing with a 3730xl DNA Analyzer
(Applied Biosystems). AITbiotech was blinded to clinical
outcomes of participants. To ensure quality control,
genotyping was done for both the forward and reverse
DNA strands.
Statistical Analysis
All statistical analyses were conducted with STATA Version
15 (StataCorp 2017). Descriptive statistics were used to sum-
marize demographics and clinical characteristics of partici-
pants. Deviation of genotypes from Hardy-Weinberg equilib-
rium was assessed using chi-squared test with one degree of
freedom. Evaluation of the associations between the BDNF
Val66Met polymorphism and CRCI was done using logistic
regression assuming a dominant model. Potential confounders
age, race, menopausal status, chemotherapy regimens, years
of education, and additionally for subjective CRCI, anxiety,
depression, and insomnia were adjusted for [24, 25].
Sensitivity analyses was performed assuming a general genet-
ic model with each genotype classified as a distinct class. To
examine the relationship between anxiety and fatigue with
BDNF genotype, linear mixed-effect models were employed
with the presence of Met allele and time incorporated as fixed
effects and intercepts varied as a random effect by each sub-
ject. To combine findings from both the original and current
cohort, adjusted odds ratios from both studies were pooled in a
fixed-effect meta-analysis using the inverse variance method.
All statistical tests were two-sided, and p values less than 0.05
were considered statistically significant.
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Sample Size Calculation
Sample size calculation was performed using Quanto 1.2.4. In
our original study, statistically significant association of CRCI
with BDNF genotype was observed for the cognitive domains
of verbal ability (OR = 0.34) and multitasking (OR = 0.37)
[7]. The latter, which yielded a smaller effect size, was used
for sample size estimation in this study. Based on an expected
allelic frequency of 0.5 in a dominant model and predicted
prevalence of impairment at 0.3 [7], a total of 167 participants
is required to yield statistical power of 80% and type 1 error of
5%. Anticipating an attrition rate of 20%, a final sample size
of 209 was targeted.
Results
Patient Characteristics
A total of 209 patients were recruited. However, 15 partici-
pants withdrew from the study (2 patients refused chemother-
apy and 13 declined to complete study procedures) and 1
patient did not provide blood samples for genotyping.
Therefore, 193 participants were included in the final analysis
(Fig. 1). The demographic characteristics of patients who
dropped out and those who remained in the study did not
differ significantly. The mean (±SD) age of participants was
51.9 ± 8.9 years old. Majority of the participants were of
Chinese ethnicity (79.8%) and had at least high school educa-
tion (84.5%). More than half received radiotherapy (66.3%),
underwent mastec tomy (63.2%), and completed
anthracycline-based chemotherapy (64.8%). Demographic
and clinical characteristics of participants in both the current
and original cohorts are comparable (Table 1).
Genotype and Allele Frequencies
All participants included in the final analysis were successful-
ly genotyped for the BDNF Val66Met polymorphism. Val/Val
and Met/Met homozygous genotypes accounted for 26.9%
and 20.7% of the observed genotypes, respectively, while
the remaining 52.3% comprised the heterozygous genotype.
Val andMet allele frequencies were approximately equivalent.
No deviation from Hardy-Weinberg equilibrium was detected
whether allele frequencies were pooled or stratified by ethnic-
ity (Table 2).
Prevalence of Subjective and Objective Cognitive
Impairment
A total of 193 participants completed FACT-Cog evaluation
and 60 patients (31.1%) reported subjective CRCI (Table 3).
Among specific cognitive domain, the highest proportion of
participants reporting cognitive decline was observed in the
mental acuity (28.5%) domains, followed by concentration
(28.0%), multi-tasking (25.9%), verbal ability (20.2%), func-
tional interference (19.2%), and memory (17.6%).
A total of 120 participants completed CANTAB assess-
ments. Participants who completed CANTAB assessments
were younger, more likely to be pre-menopausal and attained
higher education levels than those who did not. However,
there was no difference in baseline anxiety and fatigue levels,
proportion reporting subjective CRCI and BDNF Val66Met
genotypic distribution between the two groups of patients
(Supplementary Table S1). A total of 59 individuals,
representing nearly half of the patients (49.2%) experienced
decline in at least one cognitive domain (Table 3). The highest
proportion of patients with cognitive decline was reported in
the domain of sustained attention (23.3%), followed by
Eligible participants consented for study, n = 209
Withdrew from study, n = 15
Did not provide blood sample for genotyping, n = 1
Participants included in analysis, n = 193
Refused or insufficient time for 
CANTAB, n = 57
Did not complete CANTAB, n = 16
Participants analysed for CANTAB, 
n = 120
Participants analysed for FACT-Cog, 
n = 193
Fig. 1 Study flow diagram
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response speed (14.2%), working memory (14.2%), learning
and memory (12.5%), and multitasking (8.3%).
Association of BDNF Genotypes with Cognitive
Impairment
After adjusting for potential confounders including anxiety
and fatigue, Met allele carriers showed a consistent trend of
decreasing odds of subjective CRCI across all domains; how-
ever, statistical significance was only observed in memory
(OR = 0.24, 95% CI = 0.09–0.61); multitasking (OR = 0.30,
95% CI = 0.14–0.67); and mental acuity (OR = 0.46, 95%
CI = 0.21–0.99). Apart for the mental acuity domain (unad-
justed OR = 0.53, 95% CI = 0.27–1.04), adjusting for
potential confounders did not alter the significance of associ-
ation (Table 4). In contrast, no significant associations were
detected in all cognitive domains investigated for objective
CRCI in both adjusted and unadjusted analysis (Table 4).
Analysis performed assuming a general genetic model yielded
results with similar trends (Supplementary Table S2).
Trajectory of Fatigue and Anxiety and Association
with BDNF Genotypes
Mean scores of BFI and BAI, indicating fatigue and anxiety,
respectively, showed an increasing trend over time (Table 5).
Baseline fatigue and anxiety were also shown to be significant
predictors of subjective CRCI in univariate analysis
(Supplementary Table S3); however, further analysis showed
that anxiety and fatigue levels over time were not associated
with BDNF Val66Met polymorphism.
Meta-Analysis of Association between BDNF
Genotypes and Subjective CRCI
Meta-analysis of odds ratios from the original (n = 145) and
current (n = 193) cohorts showed comparable trends with con-
sistent directions of association. Significantly lower odds of
CRCI were associated with Met allele carriers in the domains
of memory (OR = 0.34, 95% CI = 0.17–0.70); multitasking
(OR = 0.33, 95% CI = 0.18–0.59); and verbal ability (OR =
0.46, 95% CI = 0.24–0.88) (Table 6). In addition, the pooled
odds ratio of subjective CRCI based on total FACT-Cog score
was also lower in Met allele carriers (OR = 0.52, 95% CI =
0.29–0.94) (Table 6). No significant heterogeneity was detect-
ed between the two studies for all domains (I2 = 0–34%).
Discussion
Findings in this well-powered study and pooled results from
both the original and current studies show that carriers of the
BDNF Met allele is associated with a trend towards lower
odds of reporting self-perceived CRCI across different do-
mains. This replicates the protective effect of BDNF
Val66Met on subjective CRCI we have observed in our pre-
vious work. Consistent with our previous report,
BDNFVal66Met was not associated with objective CRCI.
Further meta-analysis of the original and the current cohort
have also uncovered the protective effect between
BDNFVal66Met and global subjective CRCI. This is a novel
finding that has not been reported in the literature.
To date, the only other studies investigating the effect of
BDNF Val66Met polymorphism on self-perceived cognitive
function have been carried out in healthy individuals and did
not report lower odds of subjective CRCI among BDNFMet
carriers [26, 27]. Therefore, we postulate that the protective
Table 1 Comparison of demographic and clinical characteristics of
participants in the current cohort and original cohort
Current cohort Original cohort
n = 193 n = 145
Demographic characteristics
Age in years, mean (SD) 51.9 (8.9) 50.8 (8.8)
Ethnicity, n (%)
Chinese 154 (79.8) 119 (82.1)
Malay 19 (9.8) 15 (10.3)
Indian 13 (6.7) 7 (4.8)
Others 7 (3.6) 4 (2.8)
Education level, n (%)
Primary school 29 (15.0) 22 (15.2)
High school 90 (46.6) 70 (48.3)
Pre-university 35 (18.1) 29 (20.0)
Graduate/postgraduate 38 (19.7) 24 (16.6)
Unknown 1 (0.5) 0 (0.0)
Menopausal status, n (%)
Premenopausal 95 (49.2) 74 (51.0)
Postmenopausal 98 (50.8) 71 (49.0)
Clinical characteristics
Cancer staging, n (%)
Stage I 27 (14.0) 32 (22.1)
Stage II 127 (65.8) 71 (49.7)
Stage III 39 (20.2) 41 (28.3)
Radiotherapy, n (%) 128 (66.3) Not reported
Surgery, n (%) Not reported
Lumpectomy 71 (36.8)
Mastectomy 122 (63.2)
Chemotherapy, n (%)
Anthracycline-based 125 (64.8) 94 (64.8)
Non anthracycline-based 68 (35.2) 51 (35.2)
Behavioral symptoms
Baseline fatigue, mean (SD) 1.6 (1.9) 1.6 (1.7)
Baseline anxiety, mean (SD) 6.9 (7.2) 6.7 (6.1)
Baseline insomnia, mean (SD) 22.8 (26.8) 23.1 (26.9)
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effect of BDNFVal66Met polymorphism on cognitive impair-
ment is conditional on the presence of active malignancy or
ongoing cancer treatment, both which have been hypothesized
as possible causes of CRCI [25]. This discrepancy may be
explained by animal studies where the expression and release
of BDNF have been shown to be heavily dependent on other
physiological elements, such as stress and inflammation,
which are elevated in cancer patients undergoing treatment
[28]. It has also been demonstrated that as cancer patients
undergo chemotherapy, changes in plasma BDNF levels differ
between BDNF genotypes [29]. These observations indicate
that the effect of genetic polymorphisms may be mediated by
downstream mechanisms that vary in different disease states.
To further elucidate the links between BDNF Val66Met poly-
morphism and CRCI, it will be useful to investigate and com-
pare differences in gene and protein expression between
BDNF genotypes in both healthy and cancer patient popula-
tions. This will not only enhance our understanding of how
genetic factors influence the development of CRCI but also
provide insights to the pathophysiology of CRCI.
Our earlier study showed a significant association of carry-
ing the BDNF Met allele with decreased odds of self-
perceived CRCI in the FACT-Cog domains of multitasking
and verbal ability [7]. In this study, we were able to replicate
our previous findings in multitasking ability but not in verbal
ability although demographic and clinical characteristics of
both the original and current cohorts were comparable.
While similar directions of association were observed, the
effect size of carrying the Met allele was smaller and did not
achieve statistical significance (OR in this study = 0.57, OR in
original study = 0.34). A possible explanation for this non-
replication could be genetic heterogeneity, where impairment
in the verbal ability domain may not be specific to the BDNF
gene but also associated with other genes not covered in our
studies. Another possibility is the phenomenon described as
“winner’s curse” where effect sizes are often found to be
overestimated in initial genetic association studies [12, 30].
Replication attempts subsequently yield smaller effect sizes
and as a result, studies are underpowered to detect a significant
impact of genetic polymorphisms. In contrast, our meta-
analysis has detected a significant association between the
Table 2 Genotype and allele
frequencies of participants
(n = 193)
Genotype/allele Ethnic subpopulation, n (%) Pooled, n (%)
Chinese Malay Indian Othersb
Total 154 19 13 7 193
Genotype
GG (Val/Val) 35 (22.7) 10 (52.6) 4 (30.8) 3 (42.9) 52 (26.9)
GA (Val/Met) 84 (54.6) 6 (31.6) 7 (53.8) 4 (57.1) 101 (52.3)
AA (Met/Met) 35 (22.7) 3 (15.8) 2 (15.4) 0 (0.0) 40 (20.7)
Allele
G (Val) allele 154 (50.0) 26 (68.4) 15 (57.7) 10 (71.4) 205 (53.1)
A (Met) allele 154 (50.0) 12 (31.6) 11 (42.3) 4 (28.6) 181 (46.9)
p valuea 0.26 0.24 0.71 0.29 0.48
a p values of Chi-square tests to assess deviation from Hardy-Weinberg equilibrium
b “Others” include Sri Lankan, Filipino, and Burmese
Table 3 Proportion of participants with CRCI
Proportion of
participants, n (%)
Subjective CRCI (n = 193)
Summation score 60 (31.1)
Cognitive domains
Memory 34 (17.6)
Verbal ability 39 (20.2)
Concentration 54 (28.0)
Mental acuity 55 (28.5)
Functional interference 37 (19.2)
Multitasking 50 (25.9)
Decline in at least 1 domain 88 (45.6)
Objective CRCI (n = 120)
Individual test measures
RTI – Five choice reaction time 17 (14.2)
PAL – Total error (adjusted) 15 (12.5)
SWM – Between errors 5 (4.2)
SWM – Strategy 15 (12.5)
AST – Switching cost 3 (2.5)
AST – Congruency cost 3 (2.5)
AST – Reaction latency 8 (6.7)
RVP – A′ 8 (6.8)
RVP – Latency 20 (16.7)
Cognitive domains
Response speed 17 (14.2)
Learning and memory 15 (12.5)
Working memory 17 (14.2)
Multitasking 10 (8.3)
Sustained attention 28 (23.3)
Decline in at least 1 domain 59 (49.2)
Number of domains
1 40 (33.3)
2 11 (9.2)
3 7 (5.8)
4 1 (0.83)
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genetic polymorphism and global subjective CRCI, which
was not reported in the previous study. The original cohort
was not adequately powered to evaluate the effect size, and
this limitation has been overcome by the combined analysis of
both cohorts.
In contrast to subjective CRCI, we did not detect any sig-
nificant association between BDNF Val66Met polymorphism
and objective CRCI, a trend which is consistent with findings
from our previous work as well as other studies in breast and
brain tumor patients [7, 31, 32]. The lack of agreement be-
tween trends and predictors of objective and subjective CRCI
is counter-intuitive but has been commonly reported in litera-
ture [33]. Subjective reports of cognitive function are more
reflective of the ability to complete daily activities, which
require the coordination of different cognitive skills, some
which may not have been measured by specific neuropsycho-
logical tests used to assess objective cognitive function. While
these tests are widely acknowledged as the gold standard to
assess cognitive function, the importance of subjective cogni-
tive reports should not be dismissed as they portray the impact
of impaired cognition on the daily functioning of patients.
Future work in this area should emulate our study, incorporat-
ing both objective and subjective measures of cognitive func-
tion as both outcomes hold equal importance and are consis-
tently shown to be poorly correlated with each other.
Past research has suggested that subjective cognitive im-
pairment is closely linked to other chemotherapy-related
symptoms such as anxiety, depression, and fatigue hence
may be more indicative of emotional distress rather than com-
promised cognitive function [1]. One may therefore speculate
that BDNF Val66Met polymorphism may be protective
against these accompanying symptoms rather than CRCI,
explaining the lack of agreement between the association of
BDNF polymorphism with objective and subjective CRCI
observed in our study. Nevertheless, anxiety and fatigue levels
have been adjusted for in our analysis. Although we did not
observe any significant associations in this study, other genetic
association studies have also shown that unlike subjective
CRCI, anxiety, fatigue, and depression are not ameliorated
but worsened among BDNF Met carriers [34, 35].
Table 4 Association of carrying
BDNFMet allele with CRCI Variable Unadjusted analysis Adjusted analysis
OR p value OR p value
Subjective cognitive impairment
(n = 193) (n = 192)a
Total score 0.63 (0.32–1.24) 0.18 0.62 (0.29–1.30) 0.21
Memory 0.45 (0.21–0.97) 0.04b 0.24 (0.09–0.61) 0.003b
Multitasking 0.43 (0.22–0.86) 0.02b 0.30 (0.14–0.67) 0.003b
Verbal ability 0.58 (0.28–1.24) 0.16 0.57 (0.24–1.38) 0.22
Concentration 0.98 (0.48–1.99) 0.96 0.86 (0.38–1.90) 0.70
Mental acuity 0.53 (0.27–1.04) 0.07 0.46 (0.21–0.99) 0.047b
Functional interference 0.87 (0.40–1.93) 0.74 0.69 (0.27–1.75) 0.44
Objective cognitive impairment
(n = 120) (n = 119)a
Response speed 2.01 (0.54–7.49) 0.30 3.02 (0.69–13.26) 0.14
Learning and memory 1.10 (0.32–3.73) 0.88 1.58 (0.36–6.87) 0.54
Working memory 1.34 (0.40–4.43) 0.64 1.32 (0.35–4.94) 0.68
Multitasking 0.36 (0.10–1.33) 0.12 0.32 (0.06–1.70) 0.18
Sustained attention 2.12 (0.73–6.13) 0.17 3.02 (0.88–10.35) 0.08
a Insufficient covariate data for 1 participant
b p < 0.05
Table 5 Association of BDNFMet allele with fatigue and anxiety over
time
Mean scores (SD) β p value
T1 T2 T3
Fatigue (BFI)
All participants 1.64 (1.89) 1.91 (2.03) 2.23 (2.05)
Met allele carrier
No 1.39 (1.56) 2.15 (2.08) 2.40 (2.04) Reference
Yes 1.74 (1.99) 1.81 (2.01) 2.17 (2.05) − 0.07 0.77
Anxiety (BAI)
All participants 6.86 (7.23) 8.22 (8.55) 8.55 (7.66)
Met allele carrier
No 7.00 (8.79) 8.87 (8.52) 9.40 (7.42) Reference
Yes 6.82 (6.60) 7.98 (8.58) 8.23 (7.74) − 0.75 0.48
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Considering the combination of these facts, we are confident
that our observations are due to true associations of BDNF
Val66Met polymorphism with reduced odds of subjective
cognitive decline rather than the confounding effects of fa-
tigue or other psychosocial factors.
In genetic association studies, replication attempts are cru-
cial to confirm initial findings. Past studies have suggested
several genetic polymorphisms as possible predictors of
CRCI [36, 37] but to the best of our knowledge, none have
never been successfully replicated. For example, the effect of
APOE ε4 allele was first observed in breast cancer and lym-
phoma survivors, but similar associations have not been rep-
licated in similar patient populations and cognitive domains
[32, 38, 39]. The association of COMT Val158Met with cog-
nitive impairment in breast cancer survivors has only been
successfully replicated in patients with brain tumors [31].
Thus, this study is essential as it replicates observed associa-
tions of similar direction and strength in the same cognitive
domains and study population.
A limitation of our study is that a different neuropsycho-
logical test battery, CANTAB, was employed to assess objec-
tive cognitive function as the Headminder system used in the
original study was no longer commercially available. To re-
duce any potential discrepancy between Headminder and
CANTAB, we ensured that all neuropsychological tests used
were validated for similar cognitive domains. Furthermore,
the RCI calculated to measure cognitive changes is standard-
ized by dividing differences in test scores at two separate time
points by the standard error of measurement. This ensures that
score changes in both studies are comparable although differ-
ent tests were utilized. Nevertheless, we acknowledge that the
use of different cognitive assessment tools makes comparison
between studies challenging. Furthermore, meta-analysis of
findings on objective CRCI from both studies could not be
performed as different neuropsychological tools were
employed. In genetic association studies where replication
attempts and meta-analyses are highly encouraged to increase
the effective sample size for a more robust estimate of the
genetic effect, it is imperative that similar tools to measure
cognitive ability are used across different studies. It should
also be noted that a proportion of participants did not complete
CANTAB assessments. Given that patients who failed to com-
plete CANTAB assessments were older, more likely to be
post-menopausal, and received less education, the prevalence
of objective cognitive decline may have been underestimated
in this study. Nevertheless, we believe that this is unlikely to
influence the lack of association that we observed between
BDNF genotype and objective CRCI, as age, education level,
and menopausal status were controlled for in our regression
analysis. Furthermore, the BDNF Val66Met genotypic distri-
bution between participants who had and had not completed
CANTAB assessment were also found to be comparable.
In conclusion, carriers of the BDNF Met allele were
protected against global subjective CRCI, particularly in the
domains of memory, multitasking, and verbal ability. Similar
trends towards reduced odds of subjective CRCI in all other
cognitive domains were also observed in both original and
current cohorts. We have also confirmed that no association
could be detected between BDNF Val66Met polymorphism
and objective cognitive function. As cancer- and treatment-
related toxicities such as CRCI have been shown to have a
devastating impact on cancer survivors, prediction models to
estimate the risk of these toxicities should be established and
tested for clinical use, so that survivors at risk can be targeted
at an earlier stage for interventional measures to improve their
daily functioning and quality of life. Genetic markers, such as
BDNF Val66Met, should be incorporated in these prediction
models once they have been validated in other cancer
Table 6 Pooled odds ratios of
CRCI among patients carrying
BDNF Met allele (Val/Met or
Met/Met) compared to Val/Val
genotype
Domain Cohort OR
(95% CI)
Weight Pooled OR
(95% CI)
p value I2 (%)
Summation Previous 0.40 (0.16–1.04) 39.1 0.52 (0.29–0.94) 0.03a 0
Current 0.62 (0.29–1.30) 60.9
Memory Previous 0.53 (0.19–1.53) 45.7 0.34 (0.17–0.70) 0.003a 17
Current 0.24 (0.09–0.61) 54.3
Multitasking Previous 0.37 (0.15–0.91) 43.0 0.33 (0.18–0.59) < 0.001a 0
Current 0.30 (0.14–0.67) 57.0
Verbal ability Previous 0.34 (0.12–0.90) 43.0 0.46 (0.24–0.88) 0.02a 0
Current 0.57 (0.24–1.38) 57.0
Concentration Previous 0.61 (0.23–1.59) 40.9 0.75 (0.40–1.39) 0.36 0
Current 0.86 (0.38–1.90) 59.1
Mental acuity Previous 1.03 (0.37–2.86) 36.5 0.62 (0.33–1.15) 0.13 34
Current 0.46 (0.21–0.99) 63.5
Functional interference Previous 0.38 (0.13–1.14) 42.6 0.54 (0.26–1.09) 0.08 0
Current 0.69 (0.27–1.75) 57.4
a p < 0.05
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populations. Augmented with more findings from gene and
protein expression studies, this work will contribute to current
knowledge on the biochemical pathways that are involved
with the development of CRCI. This allows us to identify
potential drug targets, which can be further screened for can-
didates of pharmacological interventions to attenuate the neg-
ative impact of CRCI among cancer patients.
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